Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade in gynecological cancers showed objective responses in 13–17% of patients. | PRIMMO study protocol A phase II study combining PD-1 blockade radiation and immunomodulation to tackle cervical and uterine cancer